Market cap
$1,272 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-88 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-16.2
-
Face value
--
-
Shares outstanding
43,764,300
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
CinCor Pharma Inc (CINC)
| 136.5 | 0.1 | 136.5 | 27.4 | -- | -- | -- |
|
BSE Sensex*
| -9.3 | 2.0 | 0.1 | -5.7 | 6.6 | 8.0 | 11.2 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
CinCor Pharma Inc (CINC)
|
29.1 | 1,271.8 | 0.0 | -88.1 | -- | -21.1 | -- | 1.0 |
| 877.7 | 55,840.5 | 6,583.9 | 2,003.3 | 14.7 | 29.9 | 39.7 | 7.6 | |
| 15.5 | 1,030.7 | 0.0 | -167.9 | -- | -128.7 | -- | 5.0 | |
| 25.3 | 15,397.5 | 3,900.9 | 821.0 | 23.5 | 14.4 | 19.1 | 2.7 | |
| 10.3 | 1,884.6 | 550.0 | 458.1 | -3.3 | 45.9 | 4.1 | 1.5 | |
| 3.6 | 804.5 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 14.4 | 1,800.9 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.1 | |
| 12.9 | 904.4 | 369.4 | 12.3 | 7.5 | 5 | 67.4 | 3.4 | |
| 3.2 | 583.4 | 4.0 | -198.4 | -4,917.6 | -166.3 | -- | 7.6 | |
| 18.2 | 1,917.9 | 453.3 | -178.1 | -38.4 | -25.1 | -- | 2.9 |
Shareholding Pattern
View DetailsAbout CinCor Pharma Inc (CINC)
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of... hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts. As of February 23, 2023, CinCor Pharma, Inc. operates as a subsidiary of AstraZeneca Finance and Holdings Inc.. Read more
-
CEO & Director
Mr. Marc M. P. de Garidel
-
CEO & Director
Mr. Marc M. P. de Garidel
-
Headquarters
Waltham, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for CinCor Pharma Inc (CINC)
What is the current share price of CinCor Pharma Inc (CINC) Today?
The share price of CinCor Pharma Inc (CINC) is $29.06 (NASDAQ) as of 03-Mar-2023 09:30 EDT. CinCor Pharma Inc (CINC) has given a return of 27.4% in the last 1 years.
What is the current PB & PE ratio of CinCor Pharma Inc (CINC)?
Since, TTM earnings of CinCor Pharma Inc (CINC) is negative, P/E ratio is not available.
The P/B ratio of CinCor Pharma Inc (CINC) is 1.02 times as on 03-Mar-2023, a 79 discount to its peers’ median range of 4.96 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
What is the 52 Week High and Low of CinCor Pharma Inc (CINC)?
The 52-week high and low of CinCor Pharma Inc (CINC) are Rs -- and Rs -- as of 21-Jun-2026.
What is the market cap of CinCor Pharma Inc (CINC)?
CinCor Pharma Inc (CINC) has a market capitalisation of $ 1,272 Mln as on 03-Mar-2023. As per SEBI classification, it is a company.
Should I invest in CinCor Pharma Inc (CINC)?
Before investing in CinCor Pharma Inc (CINC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.